Sanofi's touted eczema drug hits study goal, but data fall short of expectations

Retrieved on: 2025-09-05 00:08:56

Tags for this article:

Sanofi

CAC 40

Pharmaceutical companies

Regeneron Pharmaceuticals

Dupilumab

Amgen

CD134

Click the tags to see associated articles and topics

Sanofi's touted eczema drug hits study goal, but data fall short of expectations. View article details on hiswai:

Excerpt

Dive Brief: Sanofi shares dropped after the French drugmaker reported results from a highly anticipated study of a new kind of medicine for eczema ...

Article found on: www.biopharmadive.com

View Original Article